Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilars Forum: How Do You Create A Brand-Generic Coalition? Don’t Talk About Naming

Executive Summary

Group of 11 companies is focusing on biosimilar reimbursement and educational issues important to market formation.

You may also be interested in...



Biosimilars Forum’s New Executive Director Faces Down Challenge Of Interchangeability Confusion

Juliana Reed, who just moved from Pfizer to head the trade group, hopes scientific advances will eventually eliminate the need for the interchangeability designation, but for now the association is educating stakeholders in preparation for the 2023 launch of Humira biosimilars.

PhRMA Embraces Teva Across Brand-Generic Divide

PhRMA accepts Teva's request for membership; BIO rejected Teva five years ago.

Biosimilar User Fee Talks Begin With Industry Negotiating Amongst Itself

FDA asks negotiators from the four industry groups to coordinate proposed changes as BsUFA renewal talks get underway.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS056856

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel